Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung Cancer - Episode 2

ADCs in Development for the Treatment of Lung Cancer

,

Drs Martin Dietrich and Wade Thomas Iams discuss the differences between the targets, payloads, and linker technologies of the antibody drug conjugates in development for lung cancer.

EP. 1: Overview of Antibody Drug Conjugates in Lung Cancer
Now Viewing
EP. 2: ADCs in Development for the Treatment of Lung Cancer
EP. 3: Targeting CEACAM5 in Patients with Non-Small Cell Lung Cancer
EP. 4: HER2-Directed Agents in NSCLC
EP. 5: Targeting HER3 in EGFR-Mutant NSCLC
EP. 6: Exploring TROP2 Expression in Patients with NSCLC

Related Content:

Expanding Horizons: Antibody Drug Conjugates in Non-Small Cell Lung CancerLung Cancer
Examining 3-Year Update Data from the CASPIAN Trial
cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
Dr Punekar on the Evaluation of NT-112 in KRAS G12D+ Advanced Solid Tumors